Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Following Failure of Prior Tyrosine Kinase Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2016
At a glance
- Drugs Ponatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms GIST
- Sponsors ARIAD Pharmaceuticals
- 27 Oct 2016 Status changed from active, no longer recruiting to completed.
- 11 Feb 2016 Planned End Date changed from 1 Jun 2016 to 1 May 2016, as reported by ClinicalTrials.gov record.
- 11 Feb 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Feb 2015, as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History